Content Type: Article

  • Recent Employment Law Updates

    Recent Employment Law Updates

    ARTICLE / CLIENT ALERT

    Recent Employment Law Updates

    June 7, 2023

    Read time: 5 min

    Key takeaways
    Overview

    New York State Updates Its Model Sexual Harassment Policy

    The New York State Department of Labor (“NYDOL”) updated New York State’s Sexual Harassment Model Policy. The template document is provided by New York State to help employers comply with existing New York State legislation, previously discussed here, which requires employers to provide all employees with a sexual harassment and workplace discrimination prevention policy, annual sexual harassment and discrimination prevention training, and a copy of the policy on paper or by email at the time of hiring and annually during training. Employers are not required to adopt the model policy, but those that do not must ensure that their policy meets the minimum standards previously set forth by the NYDOL and should consider revising their policy to incorporate the updates to the model.

    The updated policy now includes an explanation of gender diversity and emphasizes that gender discrimination, including gender role stereotyping and treating employees differently because of their gender identity, is sexual harassment. The updated policy also provides additional examples of sexual harassment (e.g., intentional misuse of preferred pronouns, dress codes that place emphasis on women’s attire), and illustrates issues that may emerge in the context of remote work (e.g., remarks made via virtual platforms/messaging apps). Other notable revisions include an explanation that under New York law, sexual harassment does not need to be “severe or pervasive” to be illegal, that intent is not a defense under the law, an added section regarding bystander intervention, a more comprehensive discussion of retaliation in the harassment context, a statement that the policy “should be considered applicable to all protected classes,” and the contact information for New York’s sexual harassment hotline that was implemented last summer.

    New York State also updated its “Combating Sexual Harassment” resource page to include new toolkits for employers and workers, updated Frequently Asked Questions, as well as a new training slide deck and accompanying script, and other materials employers can utilize for employee training purposes.

    Updates Regarding the Use of Artificial Intelligence in Hiring

    On April 6, 2023, the New York City Department of Consumer and Worker Protection announced that enforcement of its new Artificial Intelligence (“AI”) bias law will be delayed until July 5, 2023. The law, previously discussed here, regulates employers’ use of automated employment decision tools as part of their hiring practices. The proposed rules discussed were also adopted with minor adjustments.

    On May 18, 2023, the Equal Employment Opportunity Commission released a technical assistance document discussing the application of Title VII of the Civil Rights Act to an employer’s use of automated systems in employment selection procedures, including those that use AI. Among other developments, the document notes that in many cases an employer can be responsible under Title VII for its use of AI in employment selection procedures that discriminate against a protected classification, even if the tool was designed or administered by another entity, such as a software vendor.

    U.S. Department of Labor Publishes New FLSA and FMLA Posters

    The U.S. Department of Labor has issued an updated Fair Labor Standards Act (“FLSA”) poster and an updated Family and Medical Leave Act (“FMLA”) poster. The posters must be displayed by employers in a conspicuous place where they can be readily viewed. New York State employers must also make the posters available electronically.

    Updated Summary of Rights Under the Fair Credit Reporting Act Published

    On March 17, 2023, the Consumer Financial Protection Bureau published a revised version of “A Summary of Your Rights Under the Fair Credit Reporting Act” (“Summary”). As discussed here, to comply with the Fair Credit Reporting Act, the Summary must be provided to applicants and employees when conducting background checks and when taking an adverse employment action in response to a background check. Though the revisions to the Summary are non-substantive, including formatting changes and corrections to contact information for several federal agencies, employers and consumer reporting agencies must update their forms by March 20, 2024.

    Forms I-9 Completed Remotely During Pandemic Must Be Updated in Person

    The temporary flexibility allowing completion of the Form I-9 remotely when employees were working remotely ends on July 31, 2023. U.S. Immigration and Customs Enforcement (“ICE”) recently announced that employers must complete, by Aug. 30, 2023, in-person physical document inspections for employees whose documents were inspected remotely. Additional guidance on updating the Form I-9 is provided here.

    New York City Adds Height and Weight as Protected Characteristics

    The New York City Human Rights Law was amended to add height and weight to the list of covered protected characteristics. Covered employers will be prohibited from discriminating, harassing or retaliating against any individual because of their height or weight, except if height or weight is a bona fide occupational qualification. The law will go into effect on Nov. 22, 2023.

    Authored by Mark E. Brossman, Ronald E. Richman, Martin L. Schmelkin, Max Garfield, Scott A. Gold, Donna K. Lazarus, Laura R. Horowitz and Michelle M. Orge.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2023 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Mark E. Brossman

    Partner

    New York – 919 Third Avenue

    Ronald E. Richman

    Partner

    New York – 919 Third Avenue

    Martin L. Schmelkin

    Partner

    New York – 919 Third Avenue

    Max Garfield

    Partner

    New York – 919 Third Avenue

    Donna K. Lazarus

    Partner

    New York – 919 Third Avenue

    Michelle M. Orge

    Associate

    New York – 919 Third Avenue

    More insights

  • Top Takeaways | 2023 PPM-ASC Symposium | Leveraging Data Collaborations for Revenue Growth

    Top Takeaways | 2023 PPM-ASC Symposium | Leveraging Data Collaborations for Revenue Growth

    ARTICLE

    Top Takeaways | 2023 PPM-ASC Symposium | Leveraging Data Collaborations for Revenue Growth

    June 6, 2023

    Read time: 4 min

    Key takeaways
    Overview

    In this session, the panelists discussed the successes and challenges of a data collaboration between Gastro Health and Lynx.MD, and provided real-world insights into how a physician platform can harness its data to enhance patient care and generate additional revenue while maintaining compliance with applicable privacy and security regulations.

    Session panelists included:

    • Omer Dror, Founder and Chief Executive Officer, Lynx.MD
    • Rich Weissmark, Senior Vice President of Strategic Operations, Gastro Health
    • Moderator: Stephen Bernstein, Partner, McDermott Will & Emery
    In depth

    Top takeaways included:

    • Organizing and understanding patient data can require a large up-front investment, as it can be costly, time-consuming and challenging. This is often the largest hurdle in data collaborations; but once that step is addressed, the ability to harness the data for patient care and research can be exponentially valuable over time.
    • Data has a multitude of uses, e.g., internally within a practice to improve patient care and externally with life sciences partners and other stakeholders to analyze trends and forge innovation (provided that data shared externally is properly deidentified, or takes the form of a limited data set that is subject to proper data-use agreements). A physician practice with curated data that can be meaningfully used will be far better positioned to discuss and negotiate value-based care and alternative payment models with various payors.
    • While some data modeling focuses on just one use, the best opportunities may come from innovations that consider all of the other potential uses for the data. The specific disease states that are of interest to clinicians delivering care are often the same as those that interest life sciences companies. As a result, this is an opportunity for cost savings: collecting the data once, transforming it into separate deidentified data cuts and then using it for different purposes, which can include potential revenue-sharing opportunities relative to deidentified data sets.
    • Practices that want to develop data sets and forge data collaborations should act with intention in negotiating contracts that involve data and anticipate what data they may need in the future. If practices give away data rights too soon, it may be difficult to ensure future flexibility and opportunities for that data in the future. Contracts could be with electronic medical records (EMR) companies, pharmaceutical companies and various vendors, so practices should review these contracts closely and try to keep options open for future opportunities.
    • Healthcare data is inherently sensitive and heavily regulated. In addition to putting strong data-governance policies in place that support Health Insurance Portability and Accountability Act (HIPAA) regulations, companies looking to build a data strategy should make sure to consult with legal counsel in developing a plan to use the data. Data privacy and security, deidentification, the creation of limited data sets, data rights, and the level of trust between a physician platform and its data-sharing partners should all be considered before attempting to form a data collaboration.
    • Innovative use of technology and associated data use can be a differentiating factor in recruiting younger physicians who are excited about being able to deliver the best evidence-based care to patients. In addition to the recruitment value of the technology and innovative data use, well-organized data can also be used to leverage more efficiency from centralized care teams, particularly given current healthcare labor shortages.
    Authors
    More insights

  • Top Takeaways | 2023 Value-Based Care Symposium | Health System Innovation in Value-Based Care

    Top Takeaways | 2023 Value-Based Care Symposium | Health System Innovation in Value-Based Care

    ARTICLE

    Top Takeaways | 2023 Value-Based Care Symposium | Health System Innovation in Value-Based Care

    June 6, 2023

    Read time: 3 min

    Key takeaways
    Overview

    In this session, panelists focused on the unique challenges and opportunities facing health systems as they move into value-based care (VBC).

    Session panelists included:

    • Kate E. Koplan, MD, MPH, FACP, CPPS, Chief Quality Officer, Associate Medical Director of Quality and Patient Safety, The Southeast Permanente Medical Group, Kaiser Permanente Georgia
    • Tony Malcoun, Vice President, Advisory Services, Strategy and Growth, Premier Inc.
    • Aashish Shah, Corporate Vice President, Strategy, Product Innovation, Payer Contracting and Alignment, HCA Healthcare
    • Terri Welter, Partner, ECG Management Consultants
    • Moderator: Gary Scott Davis, Partner, McDermott Will & Emery
    In depth

    Top takeaways included:

    • From the perspective of a hospital or health system, value-based care means cost reduction, innovation and quality improvement.
    • Fee-for-service and valued-based care (i.e., risk payment models) can co-exist. A hospital or health system must consider its patient populations, lines of business and payor mix when determining which model or combination of models to implement.
    • Moving forward with the shift to VBC, although non-profit systems have struggled they can still succeed. However, success will depend on a non-profit system’s ability to properly use data and form the right partnerships.
    • Patients must be the driver in the transformation of hospitals and health systems into VBC-focused models. A hospital or health system can create patient-centric VBC models by operating from the perspective of patients and empowering patients with information.
    • Considerations for building any new partnership models include the use of data, relationship with physicians, communication and payment models.
    • Moving forward, a strong sense of partnership (including physician engagement), openness, patient focus and creativity will be important for a hospital or health system to maximize VBC.
    Authors

    Gary Scott Davis PA

    Senior Counsel

    Miami

    More insights

  • HHS Takes Steps to Resolve 340B Medicaid MCO Duplicate Discount Confusion

    HHS Takes Steps to Resolve 340B Medicaid MCO Duplicate Discount Confusion

    ARTICLE / CLIENT ALERT

    HHS Takes Steps to Resolve 340B Medicaid MCO Duplicate Discount Confusion

    June 5, 2023

    Read time: 4 min

    Key takeaways
    Overview

    On May 26, 2023, the Centers for Medicare and Medicaid Services (CMS) proposed an update to the Medicaid Drug Rebate Program (MDRP) rules, which includes provisions aimed at preventing 340B duplicate discounts on claims billed to Medicaid managed care organizations (MCOs). Duplicate discounts arise when both 340B discounts and Medicaid rebates are provided by a manufacturer for the same drug. Although drug manufacturers that participate in Medicaid are required to provide discounts on 340B drugs under the 340B Drug Pricing Program and are also required to provide state Medicaid programs with rebates under the MDRP on drugs dispensed to Medicaid beneficiaries, including Medicaid MCO enrollees, manufacturers are not required to provide both a 340B discount and a Medicaid rebate under the MDRP for the same drug.

    In depth

    Because the relevant statutory provisions do not clearly articulate whether the state Medicaid program, the Medicaid MCO or the 340B-participating provider (covered entity) is responsible for ensuring that duplicate discounts do not occur for Medicaid MCO claims, there currently is no uniform system for identifying Medicaid MCO claims for 340B drugs. In the years since Medicaid MCO drugs became eligible for rebates under the MDRP, the US Department of Health and Human Services (HHS) has generally encouraged the relevant stakeholders and affected parties to work together to develop a solution. To date, that has not occurred. It appears that HHS may finally be stepping in to develop, or at least work towards, a solution.

    Under the proposed rule, CMS would modify the standard Medicaid MCO contract requirements to require Medicaid MCOs that provide coverage of covered outpatient drugs to use unique, Medicaid-specific codes and group numbers on beneficiary insurance cards. The use of these identifiers would assist state Medicaid programs, MCOs and 340B covered entities to identify Medicaid MCO claims that might not otherwise be readily apparent as Medicaid MCO claims. Currently it is not uncommon for Medicaid MCOs to use the same group identifiers as claims for patients with private insurance. If implemented as proposed, the various stakeholders could more efficiently develop additional tools to identify such claims as being for 340B drugs or to exclude such claims for being filled using 340B drugs. CMS indicated that this change would allow the MDRP to run more efficiently, and would be helpful to all parties by ensuring that Medicaid rebates and 340B discounts are being provided appropriately. CMS proposed that this new requirement be implemented into Medicaid MCO contracts no later than the next rating period, following the effective date of the final rule adopting this provision.

    While the proposed rule would provide an important tool to assist in the development of additional policies to prevent duplicate discounts on Medicaid MCO claims, it would not itself effectuate a full solution. The proposed rule also does not address the ongoing concern among 340B covered entities that state Medicaid programs or Medicaid MCOs could expand 340B “carve out” requirements or reduce reimbursement rates on 340B drugs dispensed to Medicaid MCO enrollees, thereby removing the opportunity for 340B covered entities to obtain the benefit that Congress intended for them to receive through the 340B Program—i.e., generating revenue from 340B drug sales to enable 340B covered entities to provide and expand services in their communities.

    CMS solicited comments on the proposed change by July 25, 2023, and specifically requested comments regarding the implementation timeframe and operational issues that may arise from requiring the inclusion of unique Medicaid identifiers on Medicaid MCO beneficiary identification cards.

    Authors

    Emily Jane Cook

    Partner

    Los Angeles, Washington, DC

    Callee Donovan

    Associate

    Boston

    More insights

  • CMS Adds Stark Waiver for Independent Free-Standing Emergency Department Physician Owners

    CMS Adds Stark Waiver for Independent Free-Standing Emergency Department Physician Owners

    ARTICLE / CLIENT ALERT

    CMS Adds Stark Waiver for Independent Free-Standing Emergency Department Physician Owners

    June 2, 2023

    Read time: 4 min

    Key takeaways
    Overview

    On April 27, 2023, the Centers for Medicare and Medicaid Services (CMS) added a new blanket waiver to the nationwide Section 1135 waivers applicable to the physician self-referral law (Stark Law) that were promulgated in response to the COVID-19 pandemic. This addition provides an essential Stark Law waiver for physician owners of independent free-standing emergency departments (IFEDs) that served Medicare patients on the front lines during the pandemic. Without this new waiver, the financial relationship between an IFED and its physician owners who refer designated health services (including inpatient and outpatient hospital services) to the IFED would create a Stark Law violation necessitating refunds of the Medicare reimbursement received for such referred services.

    In depth

    CMS’s IFED waiver not only applies retroactively but also marks the only time that CMS has modified its blanket Stark Law waivers since their inception in 2020. For a comprehensive background regarding CMS’s 18 original waivers, please see our On the Subject, “CMS Issues Nationwide Blanket Waivers of Stark Law and OIG Issues an AKS Policy Statement.” IFEDs will now receive similar protections to ambulatory surgical centers (ASCs), which were also permitted to temporarily convert to hospitals during the pandemic and were afforded one of CMS’s original 18 blanket waivers in connection with their efforts to expand their capabilities during the COVID-19 pandemic. The temporary hospital enrollment for both IFEDs and ASCs ended on May 11, 2023.

    Like all of the Stark Law blanket waivers, the remuneration and referrals at issue must satisfy a COVID-19 purpose as defined in the blanket waivers, such as expanding the capacity of healthcare providers to address patient and community needs due to the COVID-19 outbreak, or shifting the diagnosis and care of patients to appropriate alternative settings because of the COVID-19 outbreak.

    CMS’s IFED waiver applies to referrals by a physician owner of a hospital that was an IFED immediately prior to its enrollment as a hospital in Medicare, provided that the following conditions are met:

    • On March 1, 2020, the hospital was licensed as an IFED by the state in which it is located and had physician ownership or investment.
    • The hospital enrolled in Medicare as a hospital during the period of the public health emergency.
    • The hospital did not increase the aggregate percentage of physician ownership or investment in the hospital after enrolling in Medicare.
    • The hospital meets the Medicare conditions of participation and other requirements not waived by CMS during the period of the public health emergency.
    • The hospital’s Medicare enrollment is not inconsistent with the emergency preparedness or pandemic plan of the state in which it is located.

    Although the additional waiver applies retroactively, it does not extend through the end of the public health emergency, which expired on May 11, 2023. Instead, the IFED waiver is effective from March 1, 2020, through April 10, 2023, which marked the end of the national emergency. CMS’s IFED Stark Law waiver provides welcome relief to the hundreds of IFEDs that otherwise were not afforded Stark Law protection in connection with their COVID-19 pandemic efforts.

    The McDermott Difference

    CMS’s new waiver came as a direct result of McDermott’s advocacy on behalf of IFEDs that converted to hospitals temporarily during the COVID-19 pandemic. Our lawyers can assist IFEDs in analyzing waiver applicability and remediating any potential regulatory exposure, including for IFEDs whose physician owners referred designated health services to the IFED between April 11 and May 11, 2023.

    Authors

    Monica Wallace

    Partner

    Chicago

    Amanda Jester

    Partner

    Austin

    More insights

  • CMS Withdraws COVID-19 Vaccination Mandate, Enhances Focus on Quality Measures

    CMS Withdraws COVID-19 Vaccination Mandate, Enhances Focus on Quality Measures

    ARTICLE / CLIENT ALERT

    CMS Withdraws COVID-19 Vaccination Mandate, Enhances Focus on Quality Measures

    June 1, 2023

    Read time: 4 min

    Key takeaways
    Overview

    Following the May 1 White House announcement that the federal government would wind down certain remaining COVID-19 vaccination requirements, on May 31, 2023, the Centers for Medicare & Medicaid Services (CMS) issued a final rule formally rescinding the Omnibus COVID-19 Health Care Staff Vaccination interim final rule (IFR). With this withdrawal, various Medicare- and Medicaid-certified healthcare facility types are no longer required to enforce COVID-19 vaccination among staff and contractors. However, CMS noted that it will now use quality reporting and value-based measures and incentives to encourage entities to keep workers “up to date” on COVID-19 vaccinations. This final rule is expected to be published on June 5, 2023, and will become effective 60 days after the date of publication in the Federal Register; however, CMS explicitly noted that it will use enforcement discretion prior to the 60-day effective date and will no longer enforce staff vaccination provisions.

    The IFR was originally published in the Federal Register on November 5, 2021, and required most Medicare- and Medicaid-certified providers and suppliers to implement policies and procedures to ensure staff were vaccinated against COVID-19 with limited exceptions. More detail on the contents of the Omnibus COVID-19 Health Care Staff Vaccination can be found in our previous client alerts: “CMS Issues COVID-19 vaccination interim final rule for healthcare facilities” and “CMS downshifts on expectations for covered healthcare provider staff COVID-19 vaccination.” CMS’s final rule removes this requirement, thereby removing COVID-19 vaccination policies and procedures for healthcare staff under the Conditions of Participation (CoPs), Conditions for Coverage (CfCs) and requirements.

    Despite its withdrawal of the IFR, CMS will continue to encourage ongoing COVID-19 vaccination through quality-related measures, such as quality reporting and value-based incentive programs. For example, the US Department of Health and Human Services (HHS) will continue to consider COVID-19 vaccinations as a quality measure that may subsequently affect ratings and payment in various “value-based purchasing” programs, including the Merit-Based Incentive Payment System (MIPS) and inpatient hospital quality reporting programs. The final rule notes that performance on these measures can be publicly posted via existing quality reporting mechanisms, such as the Hospital Compare website.

    CMS commented that its rescission of the IFR reflects its belief that “the risks targeted by the staff vaccination IFR have been largely addressed” and demonstrates a broader pivot toward vaccines for other infectious diseases, specifically influenza. The final rule also acknowledges staffing challenges created by the vaccine mandates but continues to emphasize the importance and effectiveness of COVID-19 vaccines. Moreover, the rule states that withdrawal of the vaccination requirements from the CoPs and CfCs does not prohibit facilities from establishing policies that require staff vaccinations. CMS encourages healthcare employers to “maintain evidence-based policies regarding staff vaccination for COVID-19 and other communicable diseases for which vaccination is available and recommended.”

    The final rule also makes permanent policies requiring long-term care providers to educate and offer COVID-19 vaccines to staff and residents. Accordingly, long-term care facilities must continue to provide information and offer a COVID-19 vaccine, as well as complete the appropriate documentation for these activities. The rule, however, removes expired COVID-19 testing requirements for those populations.

    In depth
    Authors

    Sandra M. DiVarco

    Partner

    Chicago

    Casey Li

    Associate

    Chicago

    More insights

  • Going ‘Green’—What Does That Mean? FTC Proposes Revisions to Green Guides

    Going ‘Green’—What Does That Mean? FTC Proposes Revisions to Green Guides

    ARTICLE / CLIENT ALERT

    Going ‘Green’—What Does That Mean? FTC Proposes Revisions to Green Guides

    June 1, 2023

    Read time: 5 min

    Key takeaways
    Overview

    As consumers actively seek more environmentally friendly products and services, companies have increased “green” advertising efforts to highlight eco-friendly claims and certifications related to carbon emissions, renewable energy and recycled materials. In response to this increase in “going green” marketing, the Federal Trade Commission (FTC) proposed revisions to its Guides for Use of Environmental Marketing Claims (Green Guides) to provide additional guidance to companies on what kinds of environmental claims can be made and how such claims must be substantiated to avoid legal challenges, penalties or negative publicity.

    On May 23, 2023, the FTC hosted a workshop titled “Talking Trash: Recyclable Claims and the Green Guides” to discuss its proposed revisions. The workshop examined the FTC’s guidance on “recyclable” advertising claims as part of its ongoing review of the Green Guides and discussed consumer perception of current and emerging recycling-related claims. A recording of the workshop is available online.

    In depth

    THE GREEN GUIDES 101

    The FTC’s Green Guides were published in 1992 to guide advertisers that make environmental claims and prevent claims that may mislead consumers. Revised in 1996, 1998 and 2012, the Green Guides provide direction around environmental marketing claim principles, consumer interpretation of claims and claim substantiation, and qualification of advertising claims to prevent deceptive practices. Marketing claims covered by the Green Guides include the following:

    • Carbon offsets
    • “Free-of” claims
    • Environmental certifications or seals
    • Non-toxic claims
    • Content that is recyclable, compostable or degradable
    • Renewable materials or energy
    • Ozone-safe/-friendly claims
    • General environmental benefit claims.

    FTC PROPOSED REVISIONS AND REQUEST FOR PUBLIC COMMENT

    The most recently revised Guides were released on October 11, 2012. Now, a decade later, the FTC has proposed revisions again—and asked for public comment on such proposals—to improve guidance for advertisers given the spike in “green” marketing by companies at large. If enacted, the proposed revisions would update guidance on claims currently covered in the Green Guides and would also introduce guidance for new claims arising out of the increased environmental research that has taken place over the last decade. These revisions could significantly impact advertisers that make “green” claims by requiring more specificity and more substantiation than before.

    The FTC’s requested public comment period closed on April 24, 2023. The FTC’s request for comments centered on the effectiveness of the current Green Guides, whether they have provided benefits or imposed costs on consumers and businesses, and whether the industry has generally complied with the guidance. The request for public comment further asked how society has changed with respect to environmental interest and causes in the last decade, and whether the Green Guides should remain mere guidance or if the FTC should propose rulemaking to formalize the principles.

    The FTC also sought comments on specific environmental marketing claims, including “recyclable” claims and the level of substantiation required to make these claims given the advancement in technology and manufacturing of recyclable products, and the increased awareness of and standards around recycling practices. The FTC sought public input on whether the existing threshold should be increased and what constitutes a “recyclable” product.

    The Guides currently do not address the terms “sustainable,” “sustainability” or “organic,” the use of which has significantly increased in the market over the past 10 years. Thus, the FTC requested comments on whether to issue new guidance on the reasonable consumer interpretation of these terms. The FTC is also contemplating whether new guidance is required for climate-change-related claims (since the current Guides only address carbon offset claims) and terms such as “net zero emissions” or other increasingly popular comparative claims that center on carbon footprints and reduced emissions. Additionally, the FTC is considering whether the Green Guides should provide guidance on claims related to energy use or energy efficiency (e.g., as they relate to electric vehicles).

    CONCLUSION

    The FTC’s focus on green claims is part of the agency’s overall increased enforcement of advertising claims across many industries recently. The FTC seeks to bring the Green Guides up to date with the public’s ever-increasing focus on the environment and companies’ use of “green” claims in marketing. Additionally, with the Biden administration’s focus on environmental impact and protection, companies are bound to increase their use of environmentally friendly products and services to keep up with the times, and in doing so, increase their “green” claims. Thus, it is important that the FTC provide clear guidance to the companies that would be impacted by the proposed Green Guides revisions.

    While it may take months for the agency to review comments and incorporate the proposed revisions, companies should act now to take inventory of all environmental claims made in advertisements or on their websites and ensure that sufficient substantiation exists and is maintained to support all claims made.

    Authors
    More insights

  • Great Britain and European Union Timelines: What Are the Key Dates for Transition?

    Great Britain and European Union Timelines: What Are the Key Dates for Transition?

    ARTICLE / CLIENT ALERT

    Great Britain and European Union Timelines: What Are the Key Dates for Transition?

    June 1, 2023

    Read time: 10 min

    Key takeaways
    Overview

    The law referred to in this article has changed. Please contact the authors for further information and an updated position.

    The Medicines and Healthcare products Regulatory Agency (MHRA) recently published long-awaited guidance confirming that there will be a delay in the implementation of new legislation for the Great Britain market and an extension to the period during which CE-marked medical devices will be accepted in the Great Britain market. The guidance followed the transitional period extensions granted by the European Union earlier this year for legacy EU devices. The time periods set out in the MHRA announcement did not reflect the phasing of the European Union’s extensions and so the position can be confusing. It is important to read the MHRA’s timelines alongside the changed EU law. This article explains the transitional arrangements and includes a handy timetable for both the EU and Great Britain markets.

    In depth

    New Great Britain Medical Device Legislation

    Under the current post-Brexit transitional arrangements set out in The Medical Devices Regulations 2002 (UK MDR), European CE-marked devices, including those certified under the old EU Medical Device Directive (EU MDD) and EU In Vitro Device Directive (EU IVDD), may be placed in the Great Britain market until 30 June 2023. New legislation was expected to implement the Great Britain regime at the same time.

    In an open letter to the sector in October 2022, the MHRA indicated these periods would be extended, however, the legislation and website guidance was not updated. This triggered an uncertain period for those navigating contradictory MHRA guidance around extensions and the continued use of CE marks and UKCA marks. This uncertainty was compounded following the European Union’s extensions of transitional periods for the new EU Medical Device Regulation (EU MDR).

    Great Britain Medical Device Legislative Timeline

    As discussed in our prior updates, the EU MDR was not implemented in Great Britain and there have been delays in the implementation of the new medical device framework.

    The MHRA has now confirmed that the new Great Britain medical device framework timeline is as follows:

    • Legislation introduced: Spring 2023
    • Post-market surveillance requirements: mid-2024
    • Full application of Great Britain legislation: 1 July 2025

    The government’s 2022 consultation response for this framework included proposals that were similar to the new EU medical device frameworks. The consultation also included the following generous transitional provisions from the date of implementation:

    • General medical devices: the sooner of certificate expiry or three years
    • In vitro diagnostic (IVD) products: the sooner of certificate expiry or five years

    These proposed transitional arrangements will not apply if there are significant changes in the design or intended purpose of the device. Additionally, all post-market requirements would continue to apply.

    The transitional periods refer to certificate expiry. Due to this wording of the consultation, it is unclear whether self-certified devices will benefit from a three-year transition, as self-certified devices (such as class I medical devices and general IVDs) are not certified by a notified body; instead the manufacturer declares conformity with the regulations.   This issue was not addressed in the MHRA’s guidance although it is widely anticipated that the transition periods will apply to these devices. Clarification on this is highly anticipated in upcoming legislation.

    Since the consultation, there have been calls for the United Kingdom to also consider reliance routes for placing medical devices in the Great Britain market (e.g., routes that would enable devices certified in other countries, such as the United States, to be placed in the Great Britain market). The government previously announced that it is exploring options for these new routes to market. Last week, the MHRA announced that new regulatory recognition routes for medicines will be established using approvals from Australia, Canada, the European Union, Japan, Switzerland, Singapore and the United States.

    Use of European CE Marks

    The new guidance also confirms that CE-marked devices will be accepted for placement in the Great Britain market until at least 30 June 2024. The MHRA confirmed that the government intends to put new legislation in place in Spring 2023 to reflect the acceptance of CE-marked medical devices in accordance with the following timelines:

    • Medical devices compliant with the EU MDD with a valid declaration and CE marking may be placed in the Great Britain market up until the sooner of expiry of certificate or 30 June 2028.
    • IVDs compliant with the EU IVDD with a valid declaration and CE marking may be placed in the Great Britain market up until the sooner of expiry of certificate or 30 June 2030.
    • Medical devices, including custom-made devices, compliant with the EU MDR and IVDs compliant with the EU in vitro diagnostic medical devices regulation (EU IVDR) with a valid declaration and CE marking may be placed in the Great Britain market up until 30 June 2030.

    The guidance follows the European Parliament’s March 2023 decision to extend the transitional provisions in the EU MDR so as to allow for an extension of time for compliance with EU MDR until 31 December 2027 or 2028, provided certain conditions are satisfied. For example, the extension periods only apply if there are no significant changes in the design and intended purpose of those devices. To benefit from the extension of the transition period, an agreement must be in place with a notified body before the expiry of the certificate.

    Self-certified devices (which are not up classed under the EU MDR) must already comply with the EU MDR or EU IVDR so these devices do not benefit from any transitional period extension.

    The time periods set out in the MHRA announcement do not reflect the phased extension periods for legacy EU devices. Thus, it is a confusing picture because the Great Britain time periods must be read together with the EU extensions.

    Timetable for EU and Great Britain Markets

    The tables below show the transitional time periods for the European Union and Great Britain.

    Devices Certified under the EU MDD with Extensions Granted for Compliance under EU MDR
    Classification Status under EU MDR European Union Great Britain
    Class I Medical Device with no notified body No transitional period. Self-certified devices that were not up classed under the EU MDR could not be placed on the EU market under the EU MDD from 26 May 2021 See below. Self-certified devices may still be placed on the Great Britain market with a UKCA mark (old UK MDR based on the EU MDD)
    Class I Medical Devices that did not require a notified body under the EU MDD but up classed to require the involvement of a notified body under the EU MDR 31 December 2028* 30 June 2028 (being the sooner of expiry of certificate or 30 June 2028)
    Class IIa and Iib non-implantables and certain well-established implantables 31 December 2028* 30 June 2028 (being the sooner of expiry of certificate or 30 June 2028)**
    Class III and other Iib implants 31 December 2027* 31 December 2027 (being the sooner of expiry of certificate or 30 June 2028)**
    Class III custom-made implantable devices 26 May 2026* 31 December 2026 (being the sooner of expiry of certificate or 30 June 2028)**

    In the European Union, the sell-off period for all medical devices has been removed, meaning that devices placed in the market before or during the transition period and in the supply chain may still be sold or made available.

    Devices Certified under the EU MDR
    All devices Ongoing provided declaration of conformity and valid certificate under the EU MDR. 30 June 2030
    Devices Certified under the EU IVDD
    Devices with no notified body certificate under the EU IVDD and which do not require a notified body certificate under the EU IVDR No transitional period. Self-certified devices that were not up classed could not be placed on the EU market under the IVDD from 26 May 2022 See below. Self-certified devices may still be placed on the Great Britain market but only with a UKCA mark (old UK MDR based on the EU IVDD)
    Devices with a notified body certificate under the EU IVDD and which require a notified body certificate under the EU IVDR Certificates issued under Annex VI IVDD or after May 2017 can be extended until 27 May 2025 26 May 2025 (being the sooner of expiry of certificate or 30 June 2030)**
    Devices with no notified body certificate that require a certificate issued by a notified body under the IVDR with a declaration of conformity dated before 26 May 2022 Class A IVD (sterile) 26 May 2027 26 May 2027 (being the sooner of expiry of certificate or 30 June 2030)**
    Class B 26 May 2027 26 May 2027 (being the sooner of expiry of certificate or 30 June 2030)**
    Class C 26 May 2026 26 May 2026 (being the sooner of expiry of certificate or 30 June 2030)**
    Class D 26 May 2025 26 May 2025 (being the sooner of expiry of certificate or 30 June 2030)**

    In the European Union, the sell-off period for all IVDs has been removed, meaning that devices placed in the market before or during the transition period and in the supply chain may still be sold or made available.

    Devices Certified under the EU IVDR
    All devices Ongoing provided declaration of conformity and valid certificate under EU MDR 30 June 2030
    Devices Certified under the UK MDR (Based on the EU MDD and EU IVDD) with a UKCA Mark
    Medical Devices UKCA The UKCA is not accepted in the EU market. If CE-marked, the above transitional periods apply June 2028***
    IVD UKCA The UKCA is not accepted in the EU market. If CE-marked, the above transitional periods apply June 2030***

    * This assumes all conditions under the EU MDR or EU IVDR transitional period extension requirements are and continue to be met.

    ** This assumes that the certificate expires at the end of the relevant EU MDR or EU IVDR transitional period. If the certificate expires or is invalid prior to that date, then that earlier date will apply.

    *** The position with respect to self-certified devices was not clearly specified in legislation but these devices are expected to benefit from a transitional period of three to five years.

    What Questions Remain?

    Manufacturers keeping pace with developing UK and EU legislation will no doubt be asking whether extending the transitional arrangements will ultimately resolve capacity issues at approved bodies and notified bodies and secure a clear route to market.

    The new UK legislation remains highly anticipated and whilst we expect that some detail may be included in the guidance, the industry will no doubt be looking for regulations that provide assurance that the United Kingdom remains a global growth market and an attractive world-class regulatory system.

    Clients and investors in the industry will be keen to understand the following questions:

    • Do the transitional periods apply to all devices, including self-certified devices?
    • What are the sell-off periods for devices placed in the Great Britain market?
    • What are the international recognition routes and what is the timing for implementation?
    • To what extent do the final legislative proposals mirror those set out in the earlier consultation, including alignment to the EU medical device regime?
    • How has the UK government addressed artificial intelligence and software as medical device regulations, including about predetermined change control?
    Authors

    Sharon Lamb

    Partner

    London – 22 Bishopsgate

    Bella North

    Senior Associate

    London – 22 Bishopsgate

    More insights

  • Texas Consumer Privacy Law Nears Governor’s Signature

    Texas Consumer Privacy Law Nears Governor’s Signature

    ARTICLE / CLIENT ALERT

    Texas Consumer Privacy Law Nears Governor’s Signature

    May 31, 2023

    Read time: 7 min

    Key takeaways
    Overview

    Texas will likely become the 11th state to pass a consumer privacy law. H.B. 4, the Texas Data Privacy and Security Act (TDPSA), was passed by both houses of the Texas legislature last week, and the bill is now headed to Governor Greg Abbott for a final signature. The TDPSA has an effective date of July 1, 2024, which is just over a year away.

    Below we provide an overview of some of the key aspects of this new Texas law.

    In depth

    What Businesses Are Subject to the TDPSA? 

    Unlike other state consumer privacy laws, the TDPSA does not include a revenue or other numerical threshold. The law applies broadly to any business or person that: (1) does business in Texas or produces a product or service consumed by a Texas resident; (2) processes or engages in the sale of personal data; and (3) is not considered a “small business” by the US Small Business Administration (except to the extent that the small business sells sensitive personal data).

    Who Is a “Consumer”?

    A “consumer” is a natural person who is a resident of Texas acting exclusively in a personal context. This means that employees and business-to-business contacts are expressly excluded from the definition of “consumer.”

    What Is “Personal Data”?

    “Personal data” is any information “that is linked or reasonably linkable to an identified or identifiable individual.” This includes pseudonymous data when the data is used in conjunction with information that reasonably links the data to an identified or identifiable individual. The term excludes deidentified data, aggregated data or publicly available information.

    Reflective of Virginia, companies do not need to include pseudonymous data (under certain circumstances) when responding to consumer requests under the TDPSA.

    Who Can Enforce? 

    The Texas Attorney General has exclusive enforcement authority. There is no private right of action. Before initiating any enforcement proceeding, the attorney general must give 30 days’ written notice and an opportunity to cure. If an enforcement action follows, violations of the TDPSA are subject to fines of up to $7,500 per violation.

    Who Is Exempt?

    The data-level and entity-level exemptions under the TDPSA closely mimic those of other state privacy laws. For example, personal information covered by laws such as the Health Insurance Portability and Accountability Act (HIPAA), the Gramm-Leach-Bliley Act (GLBA), the Family Educational Rights and Privacy Act and a litany of other federal laws are exempt.

    In addition, the TDPSA does not apply to financial institutions subject to GLBA, covered entities and business associates subject to HIPAA, government entities, nonprofit organizations or higher education institutions.

    The TDPSA also exempts the use of personal data for certain specific purposes, such as compliance with law, preventing fraud or injury to others and defending legal claims (just as in various other state consumer privacy laws, including Virginia and Indiana).

    What Obligations Are Imposed?

    The TDPSA imposes what have become “standard” obligations on data controllers under state consumer privacy laws. Specifically, controllers must:

    • Limit the processing of personal data to that which is reasonably adequate, relevant and necessary for the purposes of the processing as disclosed to the consumer;
    • Take steps to implement reasonable safeguards to protect the personal data within their control;
    • Refrain from discriminating against consumers for exercising their rights, and retrain from processing personal data in violation of federal laws that prohibit discrimination;
    • Obtain freely given, specific, informed and unambiguous consent prior to processing sensitive data;
    • Provide a privacy notice that is transparent, reasonably accessible, clear and meaningful;
      • Somewhat unique compared to its peers, the TDPSA requires providing separate specific notices if you sell sensitive data and if you sell biometric data (the law includes details on specific titles and location of such notices); and
    • Ensure that contracts control relationships with their processors (the law itself includes the minimum necessary provisions of these contracts).

    What Consumer Rights Are Created by the TDPSA?

    Controllers must provide the following rights to Texas consumers:

    • Access rights, including a right to confirm whether a controller is processing any of the consumer’s personal data at all;
    • Correction rights, considering the nature of the personal data and the purposes for processing the personal data;
    • Deletion rights, with respect to the data provided by or about the consumer;
    • Opt-out rights related to the sale of personal data, targeted advertising and profiling (where profiling is being used to produce a legal or similarly significant effect);
    • Appeal rights; and
    • Data portability rights but limited to data the consumer previously provided.

    Sensitive Data

    Under the TDPSA, “sensitive data” is personal data that includes information revealing racial or ethnic origin, religious belief, mental or physical health diagnosis, sexual orientation, citizenship or immigration status, genetic or biometric data that is processed to identify someone, personal data collected from a known child (under the age of 13) and precise geolocation (location within a radius of 1,750 feet). Under the TDPSA, controllers may not collect or process (including selling), and small businesses may not sell, sensitive data without first obtaining the consumer’s freely given, specific, informed and unambiguous consent or, in the case of a child, complying with the Children’s Online Privacy Protection Act.

    Response to Consumer Inquiries

    Controllers must respond to a consumer personal data request within 45 days of receipt of the request, with a 45-day extension available. If a consumer appeals a controller’s decision to deny the consumer’s request, the appeal response must be delivered within 60 days. Similar to Virginia, if the appeal is denied, controllers must provide the consumer with a method for contacting the attorney general.

    Data Protection Impact Assessments

    The TDPSA requires controllers to document impact assessments before engaging in certain processing activities, including the following:

    • Processing for targeted marketing;
    • Sale of personal data;
    • Processing of personal data for profiling if the profiling presents a reasonably foreseeable risk of legal, deceptive, discriminatory, financial, reputational or physical harms, or other substantial injury to consumers;
    • Processing sensitive data; and
    • A catch-all category of “any processing activities involving personal data that present a heightened risk of harm to consumers.”

    As appearing throughout other state privacy laws (including Virginia, Colorado, Connecticut and Indiana), these impact assessments must analyze the benefits of the processing to the company, consumer and public, while weighing the harms and potential mitigants. The TDPSA allows for the use of impact assessments done under other state laws to count towards its own requirement, and it does not require retroactive impact assessments for processing activities occurring prior to the effective date of the law.

    When Does the TDPSA Take Effect?

    The TDPSA comes into effect on July 1, 2024.

    ***

    Creating a successful, effective, and comprehensive privacy program for your organization requires a thorough understanding of both the relevant legal obligations and the personal data subject to compliance. Setting up a program that is prepared to respond to various state privacy laws as they come into effect will save organizations time in the long run, especially as many of these laws reflect one another.

    If you have questions or need assistance in readiness work for the new state consumer laws, please contact your regular McDermott lawyer or reach out to Amy Pimentel or Allison M. Tassel.

    Check out our additional coverage on new state consumer privacy laws: 

    Florida Adds a New Twist to Consumer Privacy Patchwork 

    Tennessee Joins the Fray as Legislature Passes Consumer Privacy Law

    Consumer Privacy Law Comes to Big Sky Country as Montana Passes New Law

    Indiana Passes Consumer Privacy Bill

    Iowa’s New Privacy Law: The Basics

    Colorado Finalizes Sweeping New Privacy Rules; Iowa Joins the Fray

    Preparing for New Consumer Privacy laws in Colorado, Connecticut and Utah

    California Privacy Rights Act Takes Effect…Sort Of

    Authors

    Amy C. Pimentel

    Partner

    Boston

    More insights

  • Recent Legal Developments in the Mobility Sector (05/2023)

    Recent Legal Developments in the Mobility Sector (05/2023)

    ARTICLE

    Recent Legal Developments in the Mobility Sector (05/2023)

    May 2023

    Read time: 11 min

    Key takeaways
    Overview

    The mobility and automotive industry continues to undergo dynamic change. As the market evolves, so does the legal framework for the industry. Dr. Sebastian Keding, Dr. Heiko Kermer, Max Küttner and David G. Schäfer provide an overview of some of the recent legal developments in the market.

    I. Extension of Motor Vehicle Block Exemption Regulation

    The European Commission extended the duration of the Motor Vehicle Block Exemption Regulation („MVBER“) for another five years alongside updating the supplementary guidelines. The update provides helpful guidance for companies assessing their business practices. In particular, the updated supplementary guidance further details the assessment of handling data generated by vehicles. Subject to various conditions, the MVBER exempts vertical agreements in the motor vehicle sector from the prohibition of agreements that restrict competition. Importantly, the exemption under the MVBER only applies when the agreement contains no “hardcore” restrictions.

    Click here for further details.

    Relevant for: Legal counsel in general.

    II. German Federal Court of Justice ruling on zero floor

    The German Federal Court of Justice (Bundesgerichtshof, „BGH“) ruled on 9 May 2023 that if the lender and borrower agree in a loan agreement on a variable interest rate consisting of a reference rate plus a margin, the sum of these two components cannot become negative even if the parties have not explicitly agreed on a zero floor for such a case. Otherwise, the lender would have to pay „negative interest“ to the borrower. According to the BGH, such an interpretation would i.a. deviate from the legal principle that interest payments represent the borrower’s remuneration for the temporary transfer of the loan amount.

    Click here for further details (available only in German).

    Relevant for: Captives, finance providers.

    III. European Court of Justice ruling on VAT treatment of sale of cars sold for parts

    On 17 May 2023, the European Court of Justice (“ECJ”) ruled on the application of the profit margin scheme to the taxation of end-of-life motor vehicles which are intended to be sold for parts (Articles 311(1), 313(1), 314, 315 of the VAT Directive).

    With this ruling, the ECJ continues to develop its case law on the conditions under which the so-called profit margin scheme (Article 311 et seq. of Council Directive No 2006/112/EC of 28 November 2006 on the Common System of Value Added Tax) can be applied to trade in permanently decommissioned motor vehicles (car wrecks) or individual parts recovered therefrom. According to its previous case law, the ECJ considered the application of the margin scheme (subject to the further conditions to be met for this – cf. Art. 311 et seq. of Council Directive No 2006/112/EC of 28 November 2006) to be possible at least if individual used parts were removed from such permanently decommissioned motor vehicles by the reseller and these used parts were resold (cf. ECJ judgment of 18 January 2017, C-471/15, Sjelle Autogenbrug). In its most recent judgment of May 2023, the ECJ has now extended the scope of application of the margin scheme in principle to such cases in which the permanently immobilized motor vehicles (car wrecks) were sold as such for ‘cannibalization’ – i.e. as a whole and without prior removal of still usable used parts. The ECJ states that taxation according to the margin scheme does not necessarily require that there is an identity between the purchased and the sold item. However, a prerequisite in these latter cases is that the permanently immobilized motor vehicles still contain parts that have retained the functions they had when new so that they can be used again in their current condition or after repair, and that it is also established that these vehicles have remained in their economic cycle due to such reuse of the parts. To be distinguished from this – and thus not amenable to the margin scheme – remain, on the other hand, cases in which the permanently immobilized motor vehicles are in fact sold in order to be simply scrapped or transformed into another object (cf. ECJ judgment of 11.7.2018, C-154/17, E LATS).

    Click here for the ruling.

    Relevant for: Dealers, vehicle platforms.

    IV. Court finds T&C obligation requiring lessees to check rental vehicle condition to be invalid

    A decision by the Regional Court (Landgericht) of Frankfurt am Main highlights that consumer organizations can successfully sue mobility providers if they use invalid provisions in their general terms and conditions with end customers. The defendant, a mobility provider, required in its general terms and conditions that the lessee i.a. check the tire pressure and the operating fluids before starting the journey. The court considered this to be an unjustified deviation from the German legal princple that it is the lessor’s duty to provide the lessee with the rental object in a condition suitable for its contractual use. Another obligation imposed on the lessees, this time to use the vehicle in accordance with the manuals, the vehicle documents, and the manufacturer’s specifications was also found to be invalid by the court.The court ruling can still be appealed.

    Click here for the text of the court ruling (available only in German).

    Relevant for: Subscription and mobility provider.

    V. Unilateral determination of dealer compensation by the manufacturer found legally valid in the court ruling

    The Higher Regional Court (Oberlandesgericht) of Frankfurt am Main ruled that a car manufacturer using a quantitatively selective distribution system may under certain conditions unilaterally determine and announce dealer remuneration (consisting of basic margins and bonus payments). The court ruled that although car dealers are in a dependent relationship with car manufacturers and the manufacturer‘s unilateral determination of dealer remuneration is a hindrance to the dealers, it is not unfair in the context of a balancing of interests between the parties.

    Click here for the text of the court ruling (available only in German):

    Relevant for: Dealers, OEMs.

    VI. Extension of liability insurance requirement for certain vehicles

    The German Federal Ministry of Justice has published a first draft of a law to implement EU Directive 2021/2118 on motor vehicle third-party liability insurance. The current draft would, among other things, require self-propelled machines such as excavators, harvesters, and sweepers with a high speed between 6 and 20 km/h to be insured when used on public roads. They were previously exempted.

    Click here for further details (available only in German).

    Relevant for: Insurers, full-service equipment providers.

     

    If you would like to discuss any of the topics above or other market developments, feel free to reach out to us! We look forward to hearing from you.

    In depth
    1. Extension of Motor Vehicle Block Exemption Regulation
      The European Commission extended the duration of the Motor Vehicle Block Exemption Regulation („MVBER“) for another five years alongside updating the supplementary guidelines. The update provides helpful guidance for companies assessing their business practices. In particular, the updated supplementary guidance further details the assessment of handling data generated by vehicles. Subject to various conditions, the MVBER exempts vertical agreements in the motor vehicle sector from the prohibition of agreements that restrict competition. Importantly, the exemption under the MVBER only applies when the agreement contains no “hardcore” restrictions.

      Click here for further details.Relevant for: Legal counsel in general.

    2.  German Federal Court of Justice ruling on zero floor

      The German Federal Court of Justice (Bundesgerichtshof, „BGH“) ruled on 9 May 2023 that if the lender and borrower agree in a loan agreement on a variable interest rate consisting of a reference rate plus a margin, the sum of these two components cannot become negative even if the parties have not explicitly agreed on a zero floor for such a case. Otherwise, the lender would have to pay „negative interest“ to the borrower. According to the BGH, such an interpretation would i.a. deviate from the legal principle that interest payments represent the borrower’s remuneration for the temporary transfer of the loan amount.

      Click here for further details (available only in German).

      Relevant for: Captives, finance providers.

    3. European Court of Justice ruling on VAT treatment of sale of cars sold for parts
      On 17 May 2023, the European Court of Justice (“ECJ”) ruled on the application of the profit margin scheme to the taxation of end-of-life motor vehicles which are intended to be sold for parts (Articles 311(1), 313(1), 314, 315 of the VAT Directive).

      With this ruling, the ECJ continues to develop its case law on the conditions under which the so-called profit margin scheme (Article 311 et seq. of Council Directive No 2006/112/EC of 28 November 2006 on the Common System of Value Added Tax) can be applied to trade in permanently decommissioned motor vehicles (car wrecks) or individual parts recovered therefrom. According to its previous case law, the ECJ considered the application of the margin scheme (subject to the further conditions to be met for this – cf. Art. 311 et seq. of Council Directive No 2006/112/EC of 28 November 2006) to be possible at least if individual used parts were removed from such permanently decommissioned motor vehicles by the reseller and these used parts were resold (cf. ECJ judgment of 18 January 2017, C-471/15, Sjelle Autogenbrug). In its most recent judgment of May 2023, the ECJ has now extended the scope of application of the margin scheme in principle to such cases in which the permanently immobilized motor vehicles (car wrecks) were sold as such for ‘cannibalization’ – i.e. as a whole and without prior removal of still usable used parts. The ECJ states that taxation according to the margin scheme does not necessarily require that there is an identity between the purchased and the sold item. However, a prerequisite in these latter cases is that the permanently immobilized motor vehicles still contain parts that have retained the functions they had when new so that they can be used again in their current condition or after repair, and that it is also established that these vehicles have remained in their economic cycle due to such reuse of the parts. To be distinguished from this – and thus not amenable to the margin scheme – remain, on the other hand, cases in which the permanently immobilized motor vehicles are in fact sold in order to be simply scrapped or transformed into another object (cf. ECJ judgment of 11.7.2018, C-154/17, E LATS).

      Click here for the ruling.

      Relevant for: Dealers, vehicle platforms.

    4. Court finds T&C obligation requiring lessees to check rental vehicle condition to be invalidA decision by the Regional Court (Landgericht) of Frankfurt am Main highlights that consumer organizations can successfully sue mobility providers if they use invalid provisions in their general terms and conditions with end customers. The defendant, a mobility provider, required in its general terms and conditions that the lessee i.a. check the tire pressure and the operating fluids before starting the journey. The court considered this to be an unjustified deviation from the German legal princple that it is the lessor’s duty to provide the lessee with the rental object in a condition suitable for its contractual use. Another obligation imposed on the lessees, this time to use the vehicle in accordance with the manuals, the vehicle documents, and the manufacturer’s specifications was also found to be invalid by the court.The court ruling can still be appealed. Click here for the text of the court ruling (available only in German).Relevant for: Subscription and mobility provider.
    5. Unilateral determination of dealer compensation by the manufacturer found legally valid in the court ruling
      The Higher Regional Court (Oberlandesgericht) of Frankfurt am Main ruled that a car manufacturer using a quantitatively selective distribution system may under certain conditions unilaterally determine and announce dealer remuneration (consisting of basic margins and bonus payments). The court ruled that although car dealers are in a dependent relationship with car manufacturers and the manufacturer‘s unilateral determination of dealer remuneration is a hindrance to the dealers, it is not unfair in the context of a balancing of interests between the parties.

      Click here for the text of the court ruling (available only in German): 

      Relevant for: Dealers, OEMs.

    6. Extension of liability insurance requirement for certain vehiclesThe German Federal Ministry of Justice has published a first draft of a law to implement EU Directive 2021/2118 on motor vehicle third-party liability insurance. The current draft would, among other things, require self-propelled machines such as excavators, harvesters, and sweepers with a high speed between 6 and 20 km/h to be insured when used on public roads. They were previously exempted.

      Click here for further details (available only in German).

      Relevant for: Insurers, full-service equipment providers.

    If you would like to discuss any of the topics above or other market developments, feel free to reach out to us! We look forward to hearing from you.

    Authors

    Dr. Heiko Kermer

    Partner

    Frankfurt

    Max Küttner

    Associate

    Düsseldorf

    More insights